Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption for its long-term CBGM later this year.

Venus Concept VERO shares fell 17.9% to $2.15 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 million. As per the press release, Q4 earnings came out ...

Recent federal funding cuts to substance abuse and mental health programs threaten to deepen an already dire crisis. The ...